End of rituximab maintenance for low-tumor burden follicular lymphoma

Journal of Clinical Oncology

Volumn 32, Issue 28, 2014, Pages 3093-3095

  Friedberg, Jonathan W ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; MONOCLONAL ANTIBODY;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EXPOSURE; EDITORIAL; EVENT FREE SURVIVAL; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; LONG TERM SURVIVAL; MAINTENANCE THERAPY; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; TIME TO TREATMENT; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; WATCHFUL WAITING; DRUG EFFECTS; FEMALE; LYMPHOMA, FOLLICULAR; MALE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; TUMOR BURDEN;

EID: 84907451793     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.8328     Document Type: Editorial

References (17)

1. Tan D, Horning SJ, Hoppe RT, et al: Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: The Stanford University experience. Blood 122:981-987, 2013
2. Marcus R, Imrie K, Solal-Celigny P, et al: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579-4586, 2008
3. Friedberg JW, Taylor MD, Cerhan JR, et al: Follicular lymphoma in the United States: First report of the national LymphoCare study. J Clin Oncol 27:1202-1208, 2009
4. McLaughlin P, Grillo-Ló pez AJ, Link BK, et al: Rituximab chimeric anti- CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
5. Colombat P, Brousse N, Salles G, et al: Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: Survival analyses with 7-year follow-up. Ann Oncol 23:2380-2385, 2012
6. Hainsworth JD, Burris HA 3rd, Morrissey LH, et al: Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95:3052-3056, 2000
7. Martinelli G, Schmitz SF, Utiger U, et al: Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 28:4480-4484, 2009
8. Hainsworth JD, Litchy S, Burris HA 3rd, et al: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20:4261-4267, 2002
9. Ardeshna KM, Qian W, Smith P, et al: Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial. Lancet Oncol 15:424-435, 2014
10. Kahl BS, Hong F, Williams ME, et al: Rituximab Extended Schedule or Retreatment Trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol E4402. J Clin Oncol 32:3096-3102, 2014
11. Hainsworth JD, Litchy S, Shaffer DW, et al: Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23:1088-1095, 2005
12. Ardeshna KM, Smith P, Norton A, et al: Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advancedstage non-Hodgkin lymphoma: A randomised controlled trial. Lancet 362:516-522, 2003
13. Hiddemann W, Cheson BD: How we manage follicular lymphoma. Leukemia 28:1388-1395, 2014
14. Nabhan C, Ollberding NJ, Villines D, et al: A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas. Leuk Lymphoma 55:1288-1294, 2014
15. Nastoupil LJ, Sinha R, Byrtek M, et al: The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer 120:1830-1837, 2014
16. Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 377:42-51, 2011
17. Casulo C, Byrtek M, Dawson KL, et al: Early relapse of follicular lymphoma after R-CHOP uniquely defines patients at high risk for death: An analysis from the National LymphoCare Study. American Society of Hematology Annual Meeting and Exposition, New Orleans, LA, December 7-10, 2013 (abstr 510)